CMUH is renowned for its excellence in conducting clinical trials, and Avance Clinical specializes in early-phase clinical researchers. By combining CMUH’s extensive experience in large-scale, late-stage trials with Avance Clinical’s expertise in early-phase drug development, the partnership offers international biotech companies a seamless pathway from first-in-human studies to regulatory approval and commercialization.
“This collaboration marks is a significant step toward strengthening Taiwan’s role as a global leader in clinical research” said Yvonne Lungershausen, CEO of Avance Clinical. “By partnering with a prestigious institution like CMUH, we are creating a streamlined pathway for biotech companies to progress from early-phase trials to market. This aligns with our shared vision of supporting innovative therapies across the entire drug development journey, ensuring they reach patient efficiently and effectively.”
Professor Der-Yang Cho, Dean of CMUH, also emphasized the significance of the partnership: “We are excited to collaborate with Avance Clinical to expand international research opportunities and further strengthen our capabilities in early-phase studies. This agreement not only enhances our ability to support global biotech companies but also accelerates the delivery of innovative treatments to patients.”
With its cutting-edge research infrastructure, diverse patient population, and highly experienced clinical teams, CMUH provides an optimal environment for conducting high-quality clinical trials. This partnership with Avance Clinical underscores both organizations’ commitment to advancing medical research and fostering global collaborations that drive healthcare innovation.
